Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: Results of the prospective multicenter European trial

Urology

Volumn 60, Issue 4 SUPPL., 2002, Pages 4-9

  Djavan, Bob ^a   Remzi, Mesut ^a   Zlotta, Alexandre R ^c   Ravery, Vincent ^b   Hammerer, Peter ^d   Reissigl, Andreas ^e   Dobronski, Piotr ^f   Kaisary, Amir ^g   Marberger, Michael ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b BICHAT HOSPITAL   (France)

^c ERASME HOSPITAL   (Belgium)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f MEDICAL UNIVERSITY OF WARSAW   (Poland)

^g ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN SPECIFICITY; AREA UNDER THE CURVE; ARTICLE; ASSAY; CANCER DIAGNOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENSITY; DISEASE SEVERITY; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; TRANSRECTAL ULTRASONOGRAPHY;

EID: 0036789935     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01896-4     Document Type: Article

References (30)

1. Polascik T.J., Oesterling J.E., Partin A.W. Prostate specific antigen a decade of discovery - what we have learned and where we are going . J Urol. 162:1999;293-306.
2. Landis S.H., Murray T., Bolden S., et al. Cancer statistics, 1999. CA Cancer J Clin. 49:1999;8-31.
3. The American Cancer Society . Cancer Facts & Figures, 1998. Atlanta. 1998;14-15. 20-24.
4. Brawer M.K., Cheli C.D., Neaman I.E., et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol. 163:2000;1476-1480.
5. Catalona W.J., Richie J.P., Ahmann F.R., et al. Comparison of digital rectal examination and serum prostate-specific antigen in the early detection of prostate cancer results of a multicenter clinical trial of 6,630 men . J Urol. 151:1994;1283-1290.
6. Catalona W.J., Southwick P.C., Slawin K.M., et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology. 56:2000;255-260.
7. Miller M.C., O'Dowd G.J., Partin A.W., et al. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer impact of changing disease demographics . Urology. 57:2001;1105-1111.
8. Zhou Z., Ng P.C., Very D.L., et al. Technicon Immuno 1 PSA assay measures both free and α-1-antichymotrypsin complexed prostate-specific antigen on an equimolar basis. J Clin Lab Anal. 10:1996;155-159.
9. Lilja H., Christensson A., Matikainen M.-T., et al. Prostate-specific antigen in human serum occurs predominantly in complex with alpha-1-antichymotrypsin. Clin Chem. 37:1991;1618-1625.
10. McCormack R.T., Rittenhouse H.G., Finlay J.A., et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family a new era . Urology. 45:1995;729-744.
11. Stenman U.H., Leinonen J., Alfthan H., et al. A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer assay of the complex improves clinical sensitivity for cancer . Cancer Res. 51:1991;222-226.
12. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA. 279:1998;1542-1547.
13. Vashi A.R., Wojno K.J., Henricks W., et al. Determination of the "reflex range" and appropriate cutpoints for percent free prostate specific antigen in 413 men referred for prostatic evaluation using the AxSym system. Urology. 49:1997;19-27.
14. Junker R., Brandt B., Zechel C., et al. Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and total PSA assays. Clin Chem. 43:1997;1588-1594.
15. Nixon R.G., Meyer G.E., Blasé A.B., et al. Comparison of 3 investigational assays for the free form of prostate specific antigen. J Urol. 160:1998;420-425.
16. Woodrum D., French C., Shamel L.B. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology. 48:1996;33-39.
17. Pettersson K., Pirronen T., Seppalla M., et al. Free and complexed prostate-specific antigen in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA α-1-antichymotrypsin complex . Clin Chem. 41:1995;1480-1488.
18. Chan D.W., Kelley C.A., Partin A.W. PSA-ACT immunoassay. Problems and solutions. [abstract] Clin Chem. 42:1996;S255.
19. Kuriyama M., Ueno K., Uno H., et al. Clinical evaluation of serum prostate-specific antigen-alpha1-antichymotrypsin complex values in diagnosis of prostate cancer a cooperative study . Int J Urol. 5:1998;48-54.
20. Wu J.T., Zhang P., Liu G.H., et al. Development of an immunoassay specific for the PSA-ACT complex without the problem of high background. J Clin Lab Anal. 12:1998;14-19.
21. 1-antichymotrypsin-specific prostate-specific antigen in patients with prostate carcinoma but not in those with benign prostate hyperplasia. Clin Chem. 45:1999;422-424.
22. 1antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA. Urology. 53:1999;1160-1168.
23. Allard W.J., Zhou Z., Yeung K.K. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem. 44:1998;1216-1223.
24. Zhou Z., Armstrong E.G., Belenky A., et al. Equivalent recognition of free and ACT-complexed PSA in a monoclonal polyclonal sandwich assay is conferred by binding specificity of the monoclonal antibody. J Clin Lab Anal. 12:1998;242-249.
25. Morris D.L., Dillion P.W., Very D.L., et al. Bayer Immuno 1 PSA assay an automated, ultrasensitive method to quantitate total PSA in serum . J Clin Lab Anal. 12:1998;65-74.
26. Brawer M.K., Meyer G.E., Letran J.L., et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology. 52:1998;372-378.
27. Brawer M.K., Baukson D.O., Partin A.W., et al. Complexed PSA results of a multicenter biopsy experience . [abstract] J Urol. 161:(suppl):1999;208.
28. Croal B.L., Mitchell I.D.C., Dikie A., et al. Complexed PSA and complexed PSA/prostate volume ratio in the diagnosis of prostatic carcinoma. [abstract] Clin Chem. 45:1999;A108.
29. Maeda H., Arai Y., Aoki Y., et al. Complexed prostate-specific antigen and its volume indexes in the detection of prostate cancer. Urology. 54:1999;225-228.
30. Djavan B., Zlotta A.R., Byttebier G., et al. Prostate specific density of the transition zone for early detection of prostate cancer. J Urol. 160:1998;411-418. discussion 418-419.